UnitedHealth Group stock trades 28.19 percent below its 52-week high
UnitedHealth Group stock is trading 28.19 percent below its 52-week high, priced at EUR 331.50 as of October 5, 2026. The company recently reported strong Q2 2026 adjusted EPS of USD 6.38 and raised its full-year guidance, while analysts maintain a "Moderate Buy" consensus. Despite positive earnings and guidance, the stock remains significantly below its yearly high.
UnitedHealthcare, Aetna Tighten Medicare Advantage Networks as 2027 Costs Rise: ‘We Can’t Ignore the Realities…’
UnitedHealthcare and Aetna are planning to offer more Medicare Advantage plans with tighter provider networks by 2027 due to rising medical costs and financial pressures. This shift comes as Medicare Advantage premiums are projected to fall, leading to a potential trade-off for seniors who might face changes in their in-network doctors and hospitals. The Centers for Medicare & Medicaid Services (CMS) is encouraging beneficiaries to compare options during open enrollment, while insurers emphasize the need to adapt to the healthcare system's financial realities.
UnitedHealth Group stock gains 1.83 percent as plans change for 2027
UnitedHealth Group (UNH) stock rose 1.83% to $371.90 after the company discontinued Medicare Advantage plans covering 390,000 members for 2027, focusing on profitability. This decision follows strong second-quarter earnings, where EPS beat consensus by $1.44, and precedes the release of third-quarter results on October 13, 2026. Despite the recent gains, the stock remains 19.4% below its 52-week high, with analysts maintaining a "Moderate Buy" consensus.
ALPS Group calls for Filipinos to take a more proactive approach to health
ALPS Group Inc., a Malaysia-based biotechnology and wellness company, is advocating for Filipinos to adopt a proactive approach to healthcare, focusing on prevention, early detection, and personalized health management. This initiative comes as noncommunicable diseases were responsible for 68% of deaths in the Philippines in 2021. ALPS Group aims to expand its presence in the Philippines and integrate its ecosystem of health assessments, precision medicine, and wellness recommendations into daily life.
UnitedHealth Reports on Oct. 13. Here's the 1 Number I'm Watching.
UnitedHealth Group is scheduled to report its third-quarter financial results on October 13. While investors will scrutinize revenue and earnings per share, the author emphasizes the importance of the medical care ratio, which indicates the percentage of premiums paid out for claims. This metric is crucial for assessing the insurer's profitability and will reveal if UnitedHealth maintained its efforts to lower it.
Progyny Inc. Stock Grades | PGNY
This article provides a stock overview for Progyny Inc. (PGNY), including its stock grades, analyst ratings, key financial metrics such as market value, EPS, and P/E ratio, and a brief company description. It also lists peer companies and data providers.
What Dementia Care Really Costs and How to Prepare
Dementia care is a significant financial burden due to its long duration and increasing care needs as the disease progresses. Costs can range from hundreds of thousands to over a million dollars, with national median monthly expenses for different care types presented. Families typically cover these costs through out-of-pocket payments, long-term care insurance, or Medicaid as a last resort, emphasizing the importance of early financial planning.
MinuteClinic is helping connect more Americans to care
MinuteClinic is expanding access to care by offering affordable and convenient in-person, virtual, and digital health options, addressing issues like long wait times and high costs. It provides services ranging from acute illness treatment and preventive care to chronic condition management and weight loss support. The initiative also aims to help close the primary care gap by offering accessible ongoing care through its clinics and virtual platforms.
Dealbook: DAI Closes On HCA Deal; At Home Harmony Raises $4.7M
Deaconess Associations Incorporated (DAI) has acquired 24 home health and seven hospice locations from HCA Healthcare, expanding its reach across eight states. Separately, At Home Harmony secured $4.7 million in funding for its home-based primary care and other services, while Basalt Health raised $20 million in Series A funding for its AI-powered post-acute referral platform. These developments highlight significant investment and expansion within the home healthcare sector.
BNP Paribas Exane Cuts McCormick & Company, Incorporated (NYSE:MKC) Price Target to $65.00
BNP Paribas Exane has reduced its price target for McCormick & Company (NYSE:MKC) to $65.00 from $75.00, while maintaining an "outperform" rating, suggesting a potential upside of 45.6% from its previous close. This adjustment comes despite McCormick exceeding quarterly earnings expectations with an adjusted EPS of $0.86 and revenue of $2.02 billion, and reaffirming its fiscal 2026 guidance. However, analyst sentiment remains cautious overall, reflected in a consensus "hold" rating and an average price target of $56.50, partly due to the company's organic growth of only 1.9% and a reported year-over-year decline in net income.
UnitedHealth and Humana cutting Medicare Advantage plans in 2027
UnitedHealth and Humana are discontinuing Medicare Advantage plans covering over one million seniors, with CVS Health's Aetna and Centene also scaling back. This move is a response to rising medical costs and insufficient government reimbursement, leading to insurers pulling back from less profitable markets for the 2027 enrollment year. Affected members will need to select new plans, and UnitedHealth will restructure its offerings to focus on lower-cost options.
Tenet Healthcare (THC) Outpaces Stock Market Gains: What You Should Know
Tenet Healthcare (THC) recently saw its stock price increase by 1.83% to $258.62, outperforming the S&P 500's daily gain. Despite a monthly depreciation, the company is projected to see significant EPS and revenue growth in its upcoming earnings report, with analysts anticipating a 24.05% increase in EPS and 3.4% revenue growth year-over-year. Investors are advised to monitor analyst estimate changes, as these often correlate with future stock performance, and THC currently holds a Zacks Rank of #3 (Hold).
UnitedHealth Trades at $365 as It Shuts Plans for 390,000 Medicare Advantage Members. Here’s What It Signals for 2027
UnitedHealth Group is discontinuing Medicare Advantage plans for approximately 390,000 members for 2027, part of a broader industry trend where over a million seniors will need to switch plans. Despite management's claims of competitive benefits, brokers suggest UnitedHealthcare and Humana are making significant cuts. This move, along with a projected fourth-quarter earnings decline and an increased medical care ratio, signals potential challenges and a focus on cost management and quality ratings as the company navigates regulatory risks and aims for continued revenue growth.
Ohio Rep. David Taylor Bought Up to $45K Worth of Amgen Stock
Ohio Representative David Taylor recently purchased Amgen (NASDAQ: AMGN) stock valued between $3,003 and $45,000, with the transaction occurring on September 22, 2026. This adds to his extensive trading activity over the past three years, totaling over $357 thousand, and includes trades in companies like Microsoft and Home Depot. The article highlights the importance of congressional transaction disclosures under the STOCK Act, which aims to prevent insider trading by elected officials.
Humana Inc. Research & Ratings | HUM
This article provides research and ratings for Humana Inc. (HUM), including analyst ratings, price targets, stock performance data, and financial estimates. It details the company's segments, key financial figures like EPS and dividend yield, and compares it to peers in the health insurance sector.
Grail’s cancer blood test nears landmark FDA approval, but insurance coverage looms
Grail's Galleri blood test is close to FDA approval, which would be a significant step towards wider adoption. However, securing health insurance coverage from both private insurers and government programs like Medicare is the next major hurdle for the multi-cancer early detection test. Widespread coverage could lead to a multi-billion dollar market, but concerns remain regarding follow-up costs, uncertain benefits, and the need for further research to confirm its impact on reducing cancer deaths.
McCormick & Company, Incorporated (NYSE:MKC) Given New $48.00 Price Target at Stifel Nicolaus
Stifel Nicolaus has lowered its price target for McCormick & Company, Incorporated (NYSE:MKC) from $55.00 to $48.00 while maintaining a "hold" rating. This adjustment comes despite McCormick exceeding its quarterly earnings and revenue expectations, reporting $0.86 EPS against a $0.76 consensus and $2.02 billion in revenue. The company also reaffirmed its fiscal 2026 adjusted EPS guidance and plans to repay a significant amount of debt, with institutional investors holding a substantial portion of the stock.
UnitedHealth names Hunter president. UnitedHealth Group stock sits 20.89 percent below its high
UnitedHealth Group has appointed Robert Hunter as president of UnitedHealthcare, a move aimed at margin recovery and operational modernization. The appointment comes as UnitedHealth Group's stock trades 20.89 percent below its 52-week high. The company is set to release its third-quarter 2026 results on October 13, 2026, with investors looking to see if the company can build on its strong second-quarter performance.
HCA closes home health, hospice sale to Deaconess
HCA Healthcare has completed the sale of 31 of its home health and hospice locations to Deaconess. The transaction was finalized on October 2, 2026, marking a significant change in HCA's post-acute care services. This move comes as health systems are also expanding other services to reduce reliance on emergency departments.
How Much Downside Is Left In CVS Health Stock?
CVS Health stock has fallen 12.7% in the past month, trading 22.5% below its 52-week high, despite no company-specific news. The article analyzes CVS's current financial state, noting its thin operating margins and heavy debt, which amplifies market risk. It also reviews CVS's historical performance during market shocks, particularly credit crises, where it experienced significant declines but eventually recovered.
Phillips Edison & Company Reaffirms Full Year 2026 Earnings Guidance; Increases Full Year 2026 Gross Acquisitions Guidance; Provides Investment Update
Phillips Edison & Company (PECO) has reaffirmed its full-year 2026 earnings guidance and increased its gross acquisitions guidance to a range of $600 million to $700 million. The company reported $459.7 million in assets acquired year-to-date through September 30, 2026, and anticipates 6.2% year-over-year growth in Core FFO per diluted share at the midpoint of its guidance. This update reflects the company's commitment to strategic investments in grocery-anchored shopping centers and maintaining balance sheet strength.
United Therapeutics Jumps 13% After Court Backs Key Patent Claims Against Liquidia
United Therapeutics shares surged 13% after a Delaware federal judge ruled that Liquidia's Yutrepia infringed two valid patent claims related to inhaled treprostinil for PH-ILD, causing Liquidia's stock to drop over 50%. The court invalidated four other claims, and both companies have one week to propose remedies, with United Therapeutics seeking withdrawal of Yutrepia's approval and damages, while Liquidia plans to appeal. An analyst upgraded United Therapeutics to Buy with a $728 target following the decision.
One profession with endless impact: Celebrating pharmacists
This article celebrates the impactful role of pharmacists, highlighting that their work extends far beyond dispensing medication. Pharmacists are crucial in preventing hospitalizations, educating patients, and advocating for patient safety, leveraging science, problem-solving, and compassion to make a meaningful difference in individuals' health journeys. The piece emphasizes their accessibility and evolving role within healthcare, particularly across CVS Health.
Danaher Corp Stock (DHR) Moved Down by 3.29% on Oct 1: What Investors Need To Know
Danaher Corp (DHR) stock declined by 3.29% on October 1st due to profit-taking in high-valuation life sciences and healthcare stocks, as well as investor caution ahead of its third-quarter earnings release. Despite strong fundamentals and technical buy signals from MACD, short-term price action will remain sensitive to macroeconomic sentiment and order visibility. The article also highlights company-specific risks including executive leadership transition, bioprocessing revenue deferrals, elevated valuation, and M&A balance sheet leverage with China headwinds.
Form 4 Unitedhealth Group For: 1 October By Investing.com
This article briefly reports on a Form 4 filing for UnitedHealth Group (UNH) on October 1st. It also includes general market data, news headlines, and various financial instruments and tools provided by Investing.com. The core content is very minimal, focusing only on the Form 4 announcement.
Texas AG opens prior auth probe into Blue Cross Blue Shield of Texas
Texas Attorney General Ken Paxton has launched an investigation into Blue Cross Blue Shield of Texas (BCBSTX) regarding its prior authorization and care denial processes. The probe follows numerous reports of denied or delayed coverage for medically necessary services, including a case involving a newborn. Paxton stated that the investigation aims to determine if BCBSTX has violated Texas law, emphasizing the importance of patient care over profits.
UnitedHealthcare Rolls Out 2027 Medicare Plans With $0 Premiums, Drug Copays And Broader Benefits
UnitedHealthcare (NYSE: UNH) has introduced its 2027 Medicare Advantage plans, featuring $0 premiums, reduced out-of-pocket costs, and expanded benefits to enhance accessibility and affordability for seniors. The plans include $0 copays for primary care and Tier 1 prescription drugs, as well as comprehensive dental, vision, and hearing coverage. Additionally, the insurer is modernizing its UCard technology and offering specialized plans for dual-eligible and chronic condition beneficiaries.
CVS Health Corporation (NYSE:CVS) Declares Quarterly Dividend of $0.67
CVS Health Corporation (NYSE:CVS) announced a quarterly dividend of $0.665 per share, payable on November 2nd to shareholders of record as of October 22nd. This annualizes to $2.66 with a 3.1% yield, and the dividend is well-covered by earnings with a payout ratio of 37.7%. The company recently reported strong quarterly results, exceeding revenue and EPS estimates.
This Texas agent chose Douglas Elliman because of its healthcare coverage options
Real estate agent and opera singer Austin Siebert chose Douglas Elliman for its healthcare coverage options, which are provided through a partnership with RLTYco and Solo Health. As an independent contractor, Siebert faced skyrocketing healthcare costs in the ACA marketplace. The Solo Health plan offers comprehensive, affordable, and customer-service-oriented healthcare designed for self-employed individuals, allowing Siebert to pursue his dual passions without financial strain.
Many 2027 Medicare plans may let members use one card for several covered benefits.
Elevance Health (NYSE: ELV) announced its affiliated health plans will offer 2027 Medicare Advantage plans designed to provide stability, choice, and more coordinated support, starting January 1, 2027. These plans will expand offerings for chronic conditions and aim to simplify benefit experiences, including the use of a single Benefits Prepaid Card for multiple covered benefits. The focus is on local needs, personalized support, and improved coordination for dual-eligible members and those managing chronic health conditions.
UnitedHealth, Aetna, Humana roll out 2027 Medicare Advantage plans
UnitedHealth, Aetna, and Humana have begun rolling out their Medicare Advantage plans for the year 2027. The article, authored by Nona Tepper, was published on October 1, 2026, at 10:23 AM CDT.
Elevance Health (ELV) Is Back In The Spotlight, What Is Drawing Attention?
Elevance Health (ELV) has recently drawn attention due to its share price movement, with the stock closing at US$388.82. Despite some softer short-term trading, the company's year-to-date and one-year returns are positive. The most popular narrative suggests ELV is 14% undervalued with a fair value of $451.38, driven by the expected positive impact of AI and digital platforms on cost management and net margins.
Zacks Research Has Optimistic Opinion of Humana Q3 Earnings
Zacks Research has updated its earnings estimates for Humana (NYSE:HUM), raising its Q3 2026 EPS forecast to $(1.13) from $(1.18) and projecting fiscal 2026 EPS of $9.05, while maintaining a "Hold" rating. This optimistic revision follows Humana's latest quarter, where it exceeded expectations with EPS of $7.61 and revenue of $40.89 billion, a 26.2% year-over-year increase. Despite some mixed sentiment from other analysts, the consensus price target remains $408.61, with the company also declaring a quarterly dividend of $0.885 per share.
Why home health expansions are a power play in value-based care
The article discusses how home health expansions by companies like Bayada and Addus HomeCare are strategic moves to secure value-based care contracts. These expansions are highlighted as a significant power play within the evolving landscape of healthcare.
Envestnet Asset Management Inc. Increases Position in Humana Inc. $HUM
Envestnet Asset Management Inc. significantly increased its stake in Humana Inc. by 180.2% in the second quarter of 2026, bringing its total holdings to 38,820 shares valued at $15.4 million. This move is part of a broader trend of institutional investment in Humana, with such investors now owning 92.38% of the company's stock. Despite a mixed analyst outlook, Humana reported strong financial results, surpassing earnings expectations with $7.61 EPS and $40.89 billion in revenue, and declared a quarterly dividend of $0.885 per share.
Judge Rules UnitedHealth Must Face Shareholder Suit by CalPERS
A federal judge has ruled that UnitedHealth Group Inc. must defend itself against a slimmed-down lawsuit filed by CalPERS. The lawsuit alleges UnitedHealth misled shareholders about financial transactions that boosted earnings by $3.3 billion in 2024, clearing the way for CalPERS to gather evidence on these specific claims. While certain allegations of wider misconduct and false statements were dismissed, the ruling allows a portion of the case to proceed.
UnitedHealth Group (UNH) Dips More Than Broader Market: What You Should Know
UnitedHealth Group (UNH) shares dropped 2.1% in the latest trading session, underperforming the broader market. The company is set to release its earnings on October 13, 2026, with analysts expecting a 41.1% increase in EPS year-over-year. UNH currently holds a Zacks Rank of #2 (Buy) and is trading at a discount compared to its industry average Forward P/E.
CVS Health (CVS) Declares Quarterly Dividend of $0.665 Per Share
CVS Health (CVS) has declared a quarterly dividend of $0.665 per share, payable on November 2, 2026, with an ex-dividend date of October 22. The company offers a 3.06% dividend yield, supported by a 36% payout ratio and a 5.7% 3-year dividend growth rate, indicating a sustainable income stream despite recent operational challenges. While the stock is fairly valued according to its GF Value™ and has a robust GF Score™ of 80, insider activity shows caution with significant selling and no buying in the past year.
UnitedHealth must face shareholder lawsuit by CalPERS, judge rules
A judge has ruled that UnitedHealth must face a shareholder lawsuit filed by CalPERS. The article, published on September 30, 2026, details this legal development. It also includes other news in the healthcare industry such as CMS setting a "most favored nation" Medicare drug price model and Cigna Group expecting significant savings from AI and automation.
UnitedHealth Must Face Shareholder Suit by CalPERS, Judge Rules
A federal judge has ruled that UnitedHealth Group Inc. must face a lawsuit brought by the California Public Employees’ Retirement System (CalPERS). CalPERS alleges that UnitedHealth misled shareholders about financial transactions that boosted earnings by $3.3 billion in 2024. The ruling allows the lawsuit to proceed on these specific claims of investor deception.
Site-neutral payments could save over $12B
A new analysis by the Employee Benefit Research Institute (EBRI) suggests that implementing site-neutral payments for certain high-cost, physician-administered drugs could save health plans and employers over $12 billion annually. These savings would result from paying hospital outpatient departments the same rates as physician offices for these medications, despite hospitals arguing for higher rates due to their complex patient care and stringent regulations. While patients may not see immediate cost-sharing relief, the overall reduction in spending could eventually lead to lower premiums for workers and their families.
Prior authorization, reimagined: How CVS Caremark improves access to treatment
CVS Caremark is redesigning its prior authorization process to streamline access to necessary medications, especially specialty drugs. Enhancements have significantly reduced review times, with nearly 4 million prior authorizations now approved in real-time. The company has also expanded its Touchless Prior Authorization for select specialty medications, connecting directly with electronic health records for faster approvals and reduced administrative burden on prescribers.
ইউনাইটেডহেলথ গ্রুপ স্টক আয়ের আগে EUR 329.90 এ ট্রেড করছে
ইউনাইটেডহেলথ গ্রুপ (ISIN US91324P1021) অক্টোবর 13 তারিখে তৃতীয় ত্রৈমাসিকের ফলাফল ঘোষণার আগে EUR 329.90 এ ট্রেড করছে, যা আগের দিনের EUR 330.30 এর তুলনায় 0.12 শতাংশ কম। কোম্পানির দ্বিতীয় ত্রৈমাসিকের EPS USD 6.38 ছিল, যা USD 4.94 এর সর্বসম্মত অনুমানকে ছাড়িয়ে গেছে, এবং রাজস্ব USD 112.03 বিলিয়নে পৌঁছেছে। অক্টোবর 13 এর রিপোর্ট বিনিয়োগকারীদের জন্য চিকিৎসা খরচ, মেডিকেয়ার অ্যাডভান্টেজ কর্মক্ষমতা এবং কোম্পানির পূর্ণ-বছরের দৃষ্টিভঙ্গির একটি গুরুত্বপূর্ণ মূল্যায়ন হবে, যেখানে 2026 সালের জন্য EPS নির্দেশিকা USD 19.50-20.00 এ নির্ধারিত।
UnitedHealth shows margin recovery, raises earn...
UnitedHealth is demonstrating clear margin recovery, particularly in its Medicare and Optum Health divisions, leading to raised operating earnings guidance and an improved medical care ratio. Despite challenges in Medicaid and Commercial segments, the company's stock, currently valued at 17.8 times next twelve months price-to-earnings, depends on continued margin improvement. The upcoming Q3 earnings report will be crucial for confirming the sustainability of these improvements and assessing medical cost trends.
Robert Hunter Named UnitedHealth (UNH) Insurance President
Robert Hunter has been named the new president of UnitedHealth Group's insurance division, UnitedHealthcare. This internal promotion signals a continuity of strategy for the company, which is focused on recovering from past medical cost pressures. Hunter inherits a division that has achieved earnings recovery primarily through cost control, with revenue growth having almost stopped, posing a challenge for future expansion.
CareSource, Molina to drop ACA Marketplace plans in Ohio in 2027
CareSource and Molina Healthcare of Ohio will exit the Affordable Care Act (ACA) Marketplace in Ohio in 2027, impacting approximately 54,000 current enrollees. CareSource cited rising healthcare costs and shifts in the ACA Marketplace as reasons for its decision, while Molina Healthcare Inc. reported declining profits and higher medical care ratios in its recent earnings. Ohioans affected by this change will need to select new plans during the open enrollment period for 2027, with nine other companies approved to sell individual plans on the exchange.
Here's How Much $100 Invested In UnitedHealth Group 15 Years Ago Would Be Worth Today
This article analyzes the historical performance of UnitedHealth Group (UNH) stock. It highlights that a $100 investment in UNH 15 years ago would now be worth $876.44, demonstrating the power of compounded returns. UnitedHealth Group has an average annual return of 15.28% over this period.
The Cigna Group stock after-hours at EUR 242.45: plus 1.66 percent versus prior close
The Cigna Group's stock increased by 1.66 percent to EUR 242.45 in after-hours trading on September 29, 2026. The company announced an agreement between its Cigna Global Health Benefits business and UnitedHealthcare Global, where UnitedHealthcare Global will endorse Cigna Global Health Benefits as its preferred international health insurer, withdrawing from the international private medical insurance business in several regions. Cigna Group also scheduled an Investor Day for September 30 to discuss corporate strategy and financial targets.
Nelson Advisors: Analysis of Google Health Enterprise and Weight Watchers Strategic Partnership
Nelson Advisors analyzes the strategic partnership between Google Health Enterprise and Weight Watchers, which integrates Google's Fitbit Air wearable and AI-powered software into Weight Watchers' business platform. This collaboration aims to address the challenges faced by self-insured employers in the GLP-1 era by providing a data-driven, milestone-gated approach to weight management. The partnership seeks to improve health outcomes, reduce healthcare costs, and prevent common issues like medication discontinuation and weight regain.
Medtronic (NYSE:MDT) Stock Price
This page provides an overview of Medtronic (NYSE:MDT) stock, including its current price performance, analyst consensus targets, and various user-submitted fair value narratives. It highlights recent news and updates, key financial details, and information about the company's segments and competitors. The stock is currently trading at US$89.50, with a fair value estimate of US$98.00, suggesting it is undervalued.
